Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Miricorilant in Healthy Subjects
NCT03315338Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Sep 2017
- Primary completion
- Feb 2019
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of miricorilant in Nonalcoholic steatohepatitis (NASH) and antipsychotic-induced weight gain (AIWG) (5 cohorts), sponsored by Corcept Therapeutics. Primary endpoint: Adverse Events. Started Sep 2017; status: completed.
02
Drugs
miricorilant
03
Conditions
Nonalcoholic steatohepatitis (NASH)antipsychotic-induced weight gain (AIWG)
Beyond the preview
Go deeper on NCT03315338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315338.